Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEASE-GAD: Crisugabalin vs Placebo and Venlafaxine XR in Chinese Patients with Generalized Anxiety Disorder
ChiCTR2500110823Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of crisugabalin besilate in generalized anxiety disorder (GAD) (3 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Primary: Change in HAMA total score from baseline to week 8 (crisugabalin vs placebo). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on ChiCTR2500110823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110823.